prof_horvath
Academic leader in epigenetic aging and longevity biomarkers. Shares concise, evidence‑focused commentary on new preprints, validation studies, and the commercial implications for biotechnology, diagnostics, and consumer health ingredients.
Past bets that played out
Highlights include a preprint suggesting a single gene can markedly reduce epigenetic age in primary human cells — a potentially important signal for partial‑reprogramming approaches — and a Nature report linking omega‑3 supplementation to slower biological ageing. Both items are early evidence points: the gene over‑expression work is in vitro and undisclosed, and the omega‑3 finding has uncertain translation to near‑term corporate revenues.
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
What this channel is watching now
Monitoring epigenetic clocks and longevity interventions with potential commercial impact. Top tickers of interest: AKBM.OL, CRBN.AS, RBGLY, NESN.SW (each mentioned in the platform feed). Coverage emphasises biomarker validation, preprint replication, and how findings could affect suppliers of sequencing/methylation services, nutraceutical ingredient providers, and therapeutics focused on ageing biology.
Latest videos and market context
No video content listed. Primary output is short analytical posts and thread‑style commentary on new studies and market relevance.
Prof Steve Horvath @prof_horvath Jun 10, 2025 Genuine epigenetic rejuvenation in primary cells has long been the holy...
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro, with an undisclosed gene, and no clear near‑term public‑company catalyst.
Prof Steve Horvath @prof_horvath Feb 3, 2025 Omega-3 supplements slow biological ageing Omega-3 supplements slow biol...
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
2. A side note for the epigenetic-clock aficionados. A few years ago, we developed an epigenetic clock to verify age ...
Content discusses an epigenetic clock (ENCen40+) developed to verify age claims in centenarians/supercentenarians, clarifying it is a first‑generation chronological‑age predictor rather than a mortality (risk) clock. No companies, products, funding, regulatory events, or commercial implications are provided.
Advances in precision geriatrics. GrimAge methylation clock works in centenarians. Striking new preprint from the Hen...
A preprint reports that the GrimAge DNA methylation clock predicts mortality even in cognitively healthy centenarians (n=247; HR ~1.6 per unit), supporting the clinical/biological validity of epigenetic aging biomarkers at extreme old age. Near‑term market impact is limited (academic/preprint, not a product launch), but it modestly reinforces the investment case for epigenetic biomarker development and demand for methylation/sequencing and lab services over a multi‑quarter horizon.
Proof-backed call history
Frequent commentator on epigenetic clock development and validation. Recent posts include discussion of a centenarian‑focused age verifier (ENCen40+), GrimAge performance in centenarians, and early preprints on rejuvenation and omega‑3 effects on biological ageing.
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A Steve Horvath post highlights a longevity preprint claiming that over‑expressing a single (undisclosed) gene can produce large reductions in epigenetic age estimates in primary human cells (fibroblasts/keratinocytes) using validated clocks. If replicable and translatable, this supports the broader thesis that “partial reprogramming” / gene‑expression‑based rejuvenation might be achievable with fewer factors (potentially safer, simpler delivery). However, it is an early‑stage preprint, in vitro
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
A social‑media post cites a Nature publication claiming omega‑3 supplements slow biological ageing. This is directionally positive for consumer health/supplement demand and for omega‑3/krill/algae ingredient suppliers, but it’s a single‑item evidence point with uncertain magnitude and translation into near‑term revenue/earnings for public companies.
About this channel
Prof Steve Horvath is an authority on DNA methylation clocks and ageing biomarkers. Content is evidence‑driven, focused on whether new results are replicable and how they might translate (or not) into commercial opportunities for public companies, diagnostic labs, and ingredient suppliers.
@prof_horvath
Most recognized assets
Unlock the full track record
Follow @prof_horvath for timely, concise analysis of longevity research, epigenetic biomarker advances, and their potential market implications.